




60% af kroniske sår indeholder biofilm, hvilket kan forsinke helingen¹.

Iodosorbs unikke 4-i-1 virkning har vist sig at forstyrre og hovedsaglig ødelægge udviklet biofilm fra *P. aeruginosa* (*in-vitro*)^{2,3} og samtidig accelerere sårhelingen.⁴⁻⁹

Modsat biofilmen - er resultaterne tydelige at se.


 **smith&nephew**
IODOSORB[®]
Cadexomer Matrix with Iodine

Biofilm – En årsag til forsinket sårheling

- Biofilm er dynamiske ophobninger af bakterier og svampe der lever inden for en beskyttende egenproduceret matrix af sukkerstof og protein.
- Forskning viser at 60% af alle kroniske sår indeholder biofilm.¹
- Forekomst af biofilm har vist sig at forstyrre den normale sårheling.
- Resultatet er et ikke-helende kronisk sår, der stagnerer i inflammationsfasen.
- Hvis du har behandlet et kronisk sår uden fremskridt, på trods af god sårbehandling, er det sandsynligt at du har haft med biofilm at gøre.

IODOSORB® har vist sig at forstyrre og reelt fjerne udviklet biofilm fra *P. aeruginosa* (*in-vitro*)^{2,3}

Antimikrobiel bandage performance efter 24 timers anvendelse på fuldt udviklet *P. aeruginosa* PAO1 biofilm (*in-vitro*)¹⁰



IODOSORBs unikke 4-i-1-effekt

IODOSORB er en effektiv oprensner^{4,6,11,12} – hjælper til at rense sårbanden og forberede den til effektiv sårheling.

IODOSORB har en høj absorptionskapacitet^{4,6,8,9,12,13} – bidrager til debrideringen ved at absorbere overskydende ekssudat og rester af dødt væv.^{5,7,12,14}

IODOSORB giver vedvarende frigivelse af iod^{14,15} som har et bredt spektrum af antimikrobiel effektivitet (*in-vitro*)^{8,12-14,16,17} hjælper til at reducere den mikrobielle belastning og fjerner barriererne for sårheling

- Langsom lokal frigivelse af iod.^{4,14}
- Effektiv mod et bredt spektrum af bakterier, inklusiv MRSA (*in-vitro*)^{8,12,13,14,16,17}
- Farveskift indikerer hvornår bandageskift er nødvendigt.¹⁵

Smith & Nephew har sponsoreret et webcast fra Wounds International med titlen **Understanding Biofilm-Based Wound Care; What You Need To Know**

Se webcastet her www.woundsinternational.com/webcasts



IODOSORB Bandager

Varenr	Størrelse	Pakning
66001290	IODOSORB 5g	5 stk
66001291	IODOSORB 10g	3 stk
66001292	IODOSORB 10g	5 stk
66001293	IODOSORB 17g	2 stk



IODOSORB Salve

Varenr	Størrelse	Pakning
66001298	10g	4 Tuber
66001297	20g	2 Tuber
66001299	40g	1 Tube



IODOSORB Pulver

Varenr	Størrelse	Pakning
66001286	3g	7 Breve
66001288	50g	1 Tube

Referencer

1. James, Garth A *et al.*, Biofilms in chronic wounds. Wound Repair and regeneration (2007).
2. Smith & Nephew Research Centre Work Report. #WRP-TSG015-07-003.
3. Phillips, P. L. *et al.*, Effects of Antimicrobial Agents on an (*in-vitro*) Biofilm Model of Skin Wounds. ADVANCES IN WOUND CARE (2010) 1: 299-304.
4. Sundberg J and Meller R. A retrospective review of the use of cadexomer iodine in the treatment of chronic wounds. Wounds (1997), 9(3): p 68-86.
5. Holloway GA, Johansen KH, Barnes RW *et al.*, Multicenter trial of cadexomer iodine to treat venous stasis ulcer. West J Med, (1989 Jul), 151, p35-38.
6. Orniston MC *et al.*, A randomised comparison of cadexomer iodine and a standard treatment in out-patients with chronic leg ulcers. In Cadexomer Iodine JA Fox, H Fischer eds. (1983) 63-69.
7. Moberg S *et al.*, A randomised trial of cadexomer iodine in decubitus ulcers. J Am Geriatrics Soc. (1983); 31 p462-465.
8. Lindsay G *et al.*, A study in general practice of the efficacy of cadexomer iodine in venous leg ulcers treated on alternate days. Acta Therapeutica (1986) 12, p141-148.
9. Drosou A, Falabella A, Kirsner MD. Antiseptics on Wounds: An area of controversy. Wounds (May 2003), Vol 15 no 5, p149-166.
10. Phillips PL *et al.*, Antimicrobial dressing efficacy against mature *Pseudomonas aeruginosa* biofilm on porcine skin explants. IWJ published online September 2013.
11. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Int J Dermatology (1998) 37: p390-396.
12. Troeng T *et al.*, In Cadexomer iodine. Fox JA, Fischer H (eds) (1983) p43-50.
13. Johnson A. A combative healer with no ill effect. IODOSORB in the treatment of infected wounds. Professional Nurse (Oct 1991) p60-64.
14. Skog E *et al.*, A randomised trial comparing cadexomer iodine and standard treatment in the outpatient management of chronic venous ulcers. Br J Dermatology (1983) 109, p77-83.
15. Drolshagen C and Schaffer D. Use of absorbent antimicrobial and viscous hydrogel to manage ulcers secondary to peripheral vascular disease. Poster presented at the (1999) Symposium on Advanced Wound Care, Anaheim.
16. Saliman H and Leakey A. A report to Smith & Nephew Medical Ltd. The (*in-vitro*) activity of silver Sulphadiazine and cadexomer iodine against recent clinical isolates of methicillin-resistant *Staphylococcus aureus*, methicillin-resistant coagulase-negative staphylococci and *Pseudomonas aeruginosa*. Report number 194-03-01 (March 2001).
17. Mertz PM *et al.*, Can Antimicrobials be effective without impairing wound healing? The evaluation of a cadexomer iodine ointment. Wounds (1994), 6(6), p184-193.



Wound Management
Smith & Nephew A/S
Slotsmarken 14
2970 Hørsholm

T 45 80 61 00
F 45 80 61 51

www.smith-nephew.com
www.iodosorb.com
sn.dk@smith-nephew.com

*Varemærke tilhørende Smith & Nephew
™ Alle varemærker godkendt
© Smith & Nephew februar 2014
13-10303-DK